Wisepowder has a full range of raw materials of Aging& Antiaging , and has a total quality management system.

Faʻaalia o 1-4 o le 13 results

1 2 3 4

Aging& Antiaging(Anti-aging)

O le matua o se mea tatou faia uma ae le malamalama tele i ai. O lou faiai e iai ni suiga a o e matua e ono i ai ni mea laiti i lou manatuaina poʻo lou mafaufau tomai. E faigofie lava ona faia se lisi o suiga uma e o mai ma le matua - manatua manatuaina, maanuminumi, maso maso.
Antiaging (aneti-tuai) mafai ona avea ma autu faigata e talanoaina: o se taua o loo tauina i luga o le uiga o le upu i suʻesuʻega ma vailaʻau, ma o se ituaiga mo oloa i se malosi ma e masani ona taufaʻasese
Antiaging (Aneti-tuai) ua i ai nei le tele o eseʻesega uiga masani ma talitonuga.
-Mai le faasaienisi sosaiete aneti-matutua (antiaging) suesuega faasino faapitoa i le faifai malie, puipuia, po o le toe sui le faagasologa tuai. Aʻo lumanaʻi le vaʻai atu tele le lumanaʻi, e leai lava se faʻamaoniga ma avanoa o tekinolosi e faʻaitiitia ai pe suia ai le soifua matua o tagata.
-In the medical and reputable business community, anti-aging medicine means the early detection, prevention, and treatment of age-related diseases. This is quite different from tackling the aging process itself, and a wide array of strategies and therapies are currently available. For example Alzheimer’s treatment, disease which is relate to aging.
-I totonu o le lautele pisinisi faʻapotopotoga - e aofia ai le tele o le tele o pepelo pe faʻaletino gaioiga - anti-matua o se taua ituaiga ma o se faʻaalia auala e faʻateleina faʻatau.

Antiaging powder application

I lenei tulaga, aneti-le soifua matua oloa ua avea atili ma sili lauiloa. Antiaging efuefu talosaga aofia ai:
-Skin oloa oloa
-Faʻatau maloloina oloa
-Faʻau fagu
-Faʻoaʻoga oloa
Aging&Alzheimer’s treatment
Ua atili ai ona taatele Dementia ma tausaga. E tusa ma le 3% o tagata i le va o le 65 ma le 74, 19% i le va o le 75 ma le 84, ma le toeititi afa o i latou e ova atu ma le 85 tausaga le matutua o loʻo i ai le mafaufau. faʻamaʻi o le faʻamaʻi o le Alzheimer, cerebrovascular faamaʻi, Parkinson's disease ma Lou Gehrig's disease.
O le matua o le autu lamatiaga mafuaʻaga mo Alzheimer faamaʻi. Alzheimer's o se ituaiga o dementia e mafua ai faʻafitauli i le manatuaina, mafaufau ma amioga. O faʻailoga a le Alzheimer e masani ona tupu lemu ma atili ai le leaga ile alu o le taimi, ua matuaʻi lava lava faʻalavelave i mea fai o aso uma. "Matou te iloa o le tausaga o le tasi pito sili ona taua sao i Alzheimer, o lea e le o se mea e ofo ai na matou mauaina se fualaʻau faʻatatau o loʻo aafia foi i le matua,"
Ua faamaonia mai foi e le FDA pei o Namzaric, o le tuʻufaʻatasiga o Namenda (memantine) ma Aricept, mo le togafitia o le siama e ogaoga le afaina o le Alzheimer.
Namendais (memantine) talitonu e galue e ala i le faatonutonuina glutamate, o se mea taua faiai faiʻai. A gaosia i le tele o taimi, o le glutamate e ono mafua ai le faiʻai sela le oti. Talu ai o NMDA antagonists eseese galuega mai cholinesterase inhibitors, o ituaiga e lua ituaiga vailaʻau e mafai ona faatonuina i se tuʻufaʻatasiga.
Many new products are known to be useful in treating Alzheimer’s disease. Such as J-147 powder, CMS121 powder.

Antiaging powder products

J-147 powder(1146963-51-0): J147 is something of a modern elixir of life,it’s been shown to treat Alzheimer’s disease and reverse aging in mice and is almost ready for clinical trials in humans.The team is already performing additional studies on the molecules that are altered by J147’s effect on the mitochondrial ATP synthase—which could themselves be new drug targets. J147 has completed the FDA-required toxicology testing in animals.
Alpha-lipoic acid powder(1077-28-7): Alpha-lipoic acid is a vitamin-like chemical called an antioxidant,which means that it might provide protection to the brain under conditions of damage or injury.
Ole alpha-lipoic acid e foliga mai e fesoasoani i le puipuia o nisi ituaiga sela ua afaina i le tino, ma na toe faʻafoʻiina foi le tulaga o vitamini e pei o vitamini E ma vitamini C.
O le manatuaina o le leiloa o le popole o se popolega masani i matua matutua. E talitonuina o le faʻaletonu mai faʻafitauli o le mafaufau e taua tele i le leiloa o mea.
Talu ai o le alpha-lipoic acid o se vailaʻau malosi, o lea ua suʻesuʻe ai suʻesuʻega lona mafai gafatia ona faifai lemu le alualu i luma o faʻafitauli ua iloga mai i le manatuaina o mea, pei o le Alzheimer's disease
O le mea faafefete, le ate, fatugaʻo, pili, brokoli, ma pateta o punavai lelei o le alpha-lipoic acid.
CMS121 powder(1353224-53-9): Geroprotectors are substances which have the potential to slow down the rate at which an animal ages by targeting the aging processes. The new study examines a number of compounds and identifies some that protect the neurons from harm by slowing down an aging process; the researchers named these compounds geroneuroprotectors.
I le faʻaaogaina o nei vailaʻau o se faʻavae, na faia e le au suʻesuʻe ni sui suʻesuʻe e tolu o le Alzheimer e faʻaigoaina CMS121, CAD31, ma le J147; latou faʻaaogaina tuʻusaʻo foʻi le fisetin ma le curcumin. Na faʻaalia e le vaega o nei lima uma o nei vailaʻau na faʻaitiitia ai biomarkers o le matua, faʻaopopo le ogatotonu o le ola o moa ma lelea, ma faʻaititia ai faʻailoga o le moe.

Occurrence of aging

Toto o le aafiaga o taimi i luga o le tino o le tagata, ma e tupu i tele tulaga:
-Faʻavave o le matua. Cells tausaga faavae i luga o le numera o taimi na latou toe kopiina. O se sela e mafai ona faʻataʻitaʻia e tusa ma le 50 taimi ae leʻi toe mafai ona kopiina mea masani, e mafua mai i le puʻupuʻu telomeres. O le tele o mea leaga na faia i sela e ala i fofo saoloto ma isi mea, o le tele sela e tatau ona toe faia.
-Faitauina o le matua. Hormones avea ma se vaega tele i le matua, aemaise lava i le taimi o tuputupu aʻe tamaiti ma talavou matutua. O le maualuga o le maualuga na i lalo ole olaga. O le matua tupu e aumai ai fuafua ma lapopoʻa pori. A matou faasolo ina matutua, o suiga o le hormonal e mafua ai le mamago o le paʻu ma le menopause.
-Tupulaga faʻaleagaina. Aumea leaga o fafo uma. O le afaina i laʻau, le la, taumafa leaga, oona ma le asu e afaina ai le tino. I le aluga o taimi, o nei vaega i fafo e mafai ona taʻitaʻia ai le leaga o le tino ma paʻu ai le tino i lona mafai ona tausia ma toe faaleleia sela, aano ma totoga.
-Metabolic matutua. A o agaʻi atu i lou aso, o ou sela o loʻo fesuiaʻiina pea meaʻai i le malosi, e maua mai ai ni mea e ono afaina ai. Ole auala ole metabolabol and fausiaina le malosi mafua ai le faaleagaina ole tino ile taimi. O nisi e talitonu o le faifai maliega o le metabolic faagasologa e ala i faiga e pei o faʻatapulaʻaina kalori mafai tuai le tuai tagata i tagata.
O faʻailoga masani a le Alzheimer e aofia ai le leai o se moe, feoaʻi, o le vevesi, popolega, osofaʻiga, o le le mautonu, ma le loto faʻanoanoa. Ua aʻoaʻoina e saienitisi le mafuaʻaga o nei faʻailoga, ma o loʻo latou suʻesuʻeina togafitiga fou - vailaʻau ma mea e le faʻailogaina ai le vailaau.

Tusitaiala o le:

  1. Mortimer RK, Johnston JR (1959). “Life Span of Individual Yeast Cells”. Nature. 183 (4677): 1751–1752. Bibcode:1959Natur.183.1751M. doi:10.1038/1831751a0. hdl:2027/mdp.39015078535278. PMID 13666896
  2. Experimental drug targeting Alzheimer’s disease shows anti-aging effects” (Press release). Salk Institute. 12 November 2015. Retrieved November 13, 2015.
  3. Researchers identify the molecular target of J147, which is nearing clinical trials to treat Alzheimer’s disease”. Retrieved 2018-01-30.
  4. Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature Peter T. Nelson, Irina Alafuzoff, Eileen H. Bigio, Constantin Bouras, Heiko Braak, Nigel J. Cairns, Rudolph J. Castellani, Barbara J. Crain, Peter Davies, Kelly Del Tredici, Charles Duyckaerts, Matthew P. Frosch, Vahram Haroutunian, Patrick R. Hof, Christine M. Hulette, Bradley T. Hyman, Takeshi Iwatsubo, Kurt A. Jellinger, Gregory A. Jicha, Enikö Kövari, Walter A. Kukull, James B. Leverenz, Seth Love, Ian R. Mackenzie, David M. Mann, Eliezer Masliah, Ann C. McKee, Thomas J. Montine, John C. Morris, Julie A. Schneider, Joshua A. Sonnen, Dietmar R. Thal, John Q. Trojanowski, Juan C. Troncoso, Thomas Wisniewski, Randall L. Woltjer, Thomas G. Beach J Neuropathol Exp Neurol. Author manuscript; available in PMC 2013 Jan 30. Published in final edited form as: J Neuropathol Exp Neurol. 2012 May; 71(5): 362–381. doi: 10.1097/NEN.0b013e31825018f7